We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Geographic Variability in Outcomes of IVUS-Guided Versus Angiography-Guided PCI: Insights from a Meta-Analysis of Randomized Trials

MedXY Editorial Team•Sep 15, 2026•Cardiology
drug-eluting stentsGeographic heterogeneityIntravascular UltrasoundPercutaneous Coronary Intervention

Highlight

  • IVUS-guided PCI significantly reduces cardiac death and adverse cardiovascular events overall compared to angiography-guided PCI.
  • There is substantial geographic heterogeneity: East Asian trials report pronounced benefits, whereas non-Asian trials demonstrate neutral or no significant advantage for IVUS guidance in cardiac death.
  • Reductions in target-vessel myocardial infarction, revascularization, and major adverse cardiovascular events mirror the geographic pattern seen for cardiac death.
  • Definite stent thrombosis is consistently reduced by IVUS guidance regardless of geographic location.

Study Background

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Intracoronary Imaging-Guided PCI: Updated Meta-Analysis Validates Cardiovascular Outcome BenefitsThis updated meta-analysis of 28 RCTs reveals significant reductions in cardiovascular events and mortality with intracoronary imaging-guided PCI versus angiography-guided PCI, highlighting the importance of lesion and geographic factors inSep 19, 2026Long-Term Benefits of Quantitative Flow Ratio-Guided PCI: Insights from the 5-Year FAVOR III China TrialThe FAVOR III China trial demonstrates that QFR-guided percutaneous coronary intervention significantly reduces major adverse cardiac events over 5 years, mainly by decreasing myocardial infarction and ischemia-driven revascularization compSep 11, 2026Stent Retriever Thrombectomy Reduces Infarct Size in High-Thrombus Myocardial Infarction: Insights from the NATURE TrialThe NATURE trial demonstrates that stent retriever thrombectomy combined with conventional PCI significantly reduces infarct size in STEMI patients with large thrombus burden, without increasing short-term adverse events.Sep 6, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Optimizing Antithrombotic Therapy After PCI in Atrial Fibrillation Patients: Insights from a Network Meta-Analysis
This article explores the latest evidence on antithrombotic therapy after PCI in patients with atrial fibrillation, highlighting the balance between bleeding risk and prevention of ischemic events.
Sep 1, 2026
ORBITA-CTO Trial: Evaluating the Impact of Percutaneous Coronary Intervention on Symptomatic Chronic Total Occlusion in Stable AnginaThe ORBITA-CTO multicenter, randomized, placebo-controlled trial demonstrates that PCI significantly improves angina symptoms and quality of life in patients with single-vessel CTO without bystander disease, compared to placebo.Jul 14, 2026
Ultra-Thin Sirolimus-Eluting Stents Show Noninferiority to Everolimus-Eluting Stents in Diabetic Multivessel CAD: Insights from TUXEDO-2 TrialThe TUXEDO-2 trial demonstrated that ultra-thin strut biodegradable polymer sirolimus-eluting stents are noninferior to durable polymer everolimus-eluting stents in diabetic patients with multivessel coronary artery disease at 1-year followJul 2, 2026